Compile Data Set for Download or QSAR
maximum 50k data
Found 258 Enz. Inhib. hit(s) with Target = 'Integrin alpha-V/beta-1'
TargetIntegrin alpha-V/beta-1(Homo sapiens (Human))
Pliant Therapeutics

Curated by ChEMBL
LigandPNGBDBM50538006(CHEMBL4649232)
Affinity DataKi:  0.166nMAssay Description:Displacement of [3H] C8 from human integrin alphavbeta1 incubated for 6 hrs by competition binding assayMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetIntegrin alpha-V/beta-1(Homo sapiens (Human))
Pliant Therapeutics

Curated by ChEMBL
LigandPNGBDBM50464108(CHEMBL4241824)
Affinity DataKi:  2nMAssay Description:Inhibition of integrin alphavbeta1 (unknown origin) by radioligand binding assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetIntegrin alpha-V/beta-1(Homo sapiens (Human))
Pliant Therapeutics

Curated by ChEMBL
LigandPNGBDBM50078714(CHEMBL288493 | SB-265123 | {(S)-3-[3-(Pyridin-2-yl...)
Affinity DataKi:  1.80E+4nMAssay Description:Binding affinity for integrin alpha V beta 5 receptorMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetIntegrin alpha-V/beta-1(Homo sapiens (Human))
Pliant Therapeutics

Curated by ChEMBL
LigandPNGBDBM50199337(CHEMBL3962660 | US10131658, Compound 6)
Affinity DataIC50:  0.0200nMAssay Description:Inhibition of integrin alphaVbeta1 (unknown origin)-mediated CHO cell adhesion to fibronectin preincubated for 15 to 30 mins followed by 60 min incub...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetIntegrin alpha-V/beta-1(Homo sapiens (Human))
Pliant Therapeutics

Curated by ChEMBL
LigandPNGBDBM50199337(CHEMBL3962660 | US10131658, Compound 6)
Affinity DataIC50:  0.0200nMAssay Description:Inhibition of integrin alphaVbeta1 (unknown origin)-mediated CHO cell adhesion to fibronectin preincubated for 15 to 30 mins followed by 60 min incub...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetIntegrin alpha-V/beta-1(Homo sapiens (Human))
Pliant Therapeutics

Curated by ChEMBL
LigandPNGBDBM50199345(CHEMBL3893700 | US10131658, Compound 201)
Affinity DataIC50:  0.0600nMAssay Description:Inhibition of integrin alphaVbeta1 (unknown origin)-mediated CHO cell adhesion to fibronectin preincubated for 15 to 30 mins followed by 60 min incub...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetIntegrin alpha-V/beta-1(Homo sapiens (Human))
Pliant Therapeutics

Curated by ChEMBL
LigandPNGBDBM50199345(CHEMBL3893700 | US10131658, Compound 201)
Affinity DataIC50:  0.0631nMAssay Description:Inhibition of integrin alphaVbeta1 (unknown origin)-mediated CHO cell adhesion to fibronectin preincubated for 15 to 30 mins followed by 60 min incub...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetIntegrin alpha-V/beta-1(Homo sapiens (Human))
Pliant Therapeutics

Curated by ChEMBL
LigandPNGBDBM50554030(CHEMBL4756339)
Affinity DataIC50: <0.100nMAssay Description:Inhibition of alphavbeta1 integrin (unknown origin) by solid phase binding assayMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetIntegrin alpha-V/beta-1(Homo sapiens (Human))
Pliant Therapeutics

Curated by ChEMBL
LigandPNGBDBM50554033(CHEMBL4794201)
Affinity DataIC50: <0.100nMAssay Description:Inhibition of alphavbeta1 integrin (unknown origin) by solid phase binding assayMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetIntegrin alpha-V/beta-1(Homo sapiens (Human))
Pliant Therapeutics

Curated by ChEMBL
LigandPNGBDBM50554031(CHEMBL4749110)
Affinity DataIC50: <0.100nMAssay Description:Inhibition of alphavbeta1 integrin (unknown origin) by solid phase binding assayMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetIntegrin alpha-V/beta-1(Homo sapiens (Human))
Pliant Therapeutics

Curated by ChEMBL
LigandPNGBDBM50199411(CHEMBL3951678 | US10131658, Compound 87)
Affinity DataIC50:  0.126nMAssay Description:Inhibition of integrin alphaVbeta1 (unknown origin)-mediated CHO cell adhesion to fibronectin preincubated for 15 to 30 mins followed by 60 min incub...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetIntegrin alpha-V/beta-1(Homo sapiens (Human))
Pliant Therapeutics

Curated by ChEMBL
LigandPNGBDBM50199411(CHEMBL3951678 | US10131658, Compound 87)
Affinity DataIC50:  0.130nMAssay Description:Inhibition of integrin alphaVbeta1 (unknown origin)-mediated CHO cell adhesion to fibronectin preincubated for 15 to 30 mins followed by 60 min incub...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetIntegrin alpha-V/beta-1(Homo sapiens (Human))
Pliant Therapeutics

Curated by ChEMBL
LigandPNGBDBM472699(US10836720, HIJ-1483)
Affinity DataIC50:  0.140nMAssay Description:Inhibition of alphavbeta1 integrin (unknown origin) by solid phase binding assayMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetIntegrin alpha-V/beta-1(Homo sapiens (Human))
Pliant Therapeutics

Curated by ChEMBL
LigandPNGBDBM50199196(CHEMBL3905970)
Affinity DataIC50:  0.200nMAssay Description:Inhibition of integrin alphaVbeta1 (unknown origin)-mediated CHO cell adhesion to fibronectin preincubated for 15 to 30 mins followed by 60 min incub...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetIntegrin alpha-V/beta-1(Homo sapiens (Human))
Pliant Therapeutics

Curated by ChEMBL
LigandPNGBDBM50199196(CHEMBL3905970)
Affinity DataIC50:  0.200nMAssay Description:Inhibition of integrin alphaVbeta1 (unknown origin)-mediated CHO cell adhesion to fibronectin preincubated for 15 to 30 mins followed by 60 min incub...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetIntegrin alpha-V/beta-1(Homo sapiens (Human))
Pliant Therapeutics

Curated by ChEMBL
LigandPNGBDBM50199399(CHEMBL3909977 | US10131658, Compound 212)
Affinity DataIC50:  0.25nMAssay Description:Inhibition of integrin alphaVbeta1 (unknown origin)-mediated CHO cell adhesion to fibronectin preincubated for 15 to 30 mins followed by 60 min incub...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetIntegrin alpha-V/beta-1(Homo sapiens (Human))
Pliant Therapeutics

Curated by ChEMBL
LigandPNGBDBM50199399(CHEMBL3909977 | US10131658, Compound 212)
Affinity DataIC50:  0.251nMAssay Description:Inhibition of integrin alphaVbeta1 (unknown origin)-mediated CHO cell adhesion to fibronectin preincubated for 15 to 30 mins followed by 60 min incub...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetIntegrin alpha-V/beta-1(Homo sapiens (Human))
Pliant Therapeutics

Curated by ChEMBL
LigandPNGBDBM50554032(CHEMBL4741135)
Affinity DataIC50:  0.300nMAssay Description:Inhibition of alphavbeta1 integrin (unknown origin) by solid phase binding assayMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetIntegrin alpha-V/beta-1(Homo sapiens (Human))
Pliant Therapeutics

Curated by ChEMBL
LigandPNGBDBM50199398(CHEMBL3952235 | US10131658, Compound 211)
Affinity DataIC50:  0.310nMAssay Description:Inhibition of integrin alphaVbeta1 (unknown origin)-mediated CHO cell adhesion to fibronectin preincubated for 15 to 30 mins followed by 60 min incub...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetIntegrin alpha-V/beta-1(Homo sapiens (Human))
Pliant Therapeutics

Curated by ChEMBL
LigandPNGBDBM50199197(CHEMBL3923968 | US10131658, Compound 11)
Affinity DataIC50:  0.310nMAssay Description:Inhibition of integrin alphaVbeta1 (unknown origin)-mediated CHO cell adhesion to fibronectin preincubated for 15 to 30 mins followed by 60 min incub...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetIntegrin alpha-V/beta-1(Homo sapiens (Human))
Pliant Therapeutics

Curated by ChEMBL
LigandPNGBDBM50199197(CHEMBL3923968 | US10131658, Compound 11)
Affinity DataIC50:  0.316nMAssay Description:Inhibition of integrin alphaVbeta1 (unknown origin)-mediated CHO cell adhesion to fibronectin preincubated for 15 to 30 mins followed by 60 min incub...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetIntegrin alpha-V/beta-1(Homo sapiens (Human))
Pliant Therapeutics

Curated by ChEMBL
LigandPNGBDBM50199398(CHEMBL3952235 | US10131658, Compound 211)
Affinity DataIC50:  0.316nMAssay Description:Inhibition of integrin alphaVbeta1 (unknown origin)-mediated CHO cell adhesion to fibronectin preincubated for 15 to 30 mins followed by 60 min incub...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetIntegrin alpha-V/beta-1(Homo sapiens (Human))
Pliant Therapeutics

Curated by ChEMBL
LigandPNGBDBM279570((3S)-3-[3-bromo-5-methyl-phenyl)-3-(2-(3-hydroxy-5...)
Affinity DataIC50:  0.400nMpH: 7.4 T: 2°CAssay Description:Purified human fibronectin (R&D Systems, 1918-FN) diluted to 5 μg/mL in TBS+ buffer (25 mM Tris pH 7.4, 137 mM NaCl, 2.7 mM KCl, 1 mM CaCl2, 1 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-1(Homo sapiens (Human))
Pliant Therapeutics

Curated by ChEMBL
LigandPNGBDBM50141334(3-[4-(3-Guanidino-benzoylamino)-phenyl]-2-isopropo...)
Affinity DataIC50:  0.470nMAssay Description:Binding affinity towards alpha V-beta5 receptor expressed in HEK293 cellsMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetIntegrin alpha-V/beta-1(Homo sapiens (Human))
Pliant Therapeutics

Curated by ChEMBL
LigandPNGBDBM50199335(CHEMBL3899812)
Affinity DataIC50:  0.5nMAssay Description:Inhibition of integrin alphaVbeta1 (unknown origin)-mediated CHO cell adhesion to fibronectin preincubated for 15 to 30 mins followed by 60 min incub...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetIntegrin alpha-V/beta-1(Homo sapiens (Human))
Pliant Therapeutics

Curated by ChEMBL
LigandPNGBDBM50199338(CHEMBL3932911)
Affinity DataIC50:  0.5nMAssay Description:Inhibition of integrin alphaVbeta1 (unknown origin)-mediated CHO cell adhesion to fibronectin preincubated for 15 to 30 mins followed by 60 min incub...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetIntegrin alpha-V/beta-1(Homo sapiens (Human))
Pliant Therapeutics

Curated by ChEMBL
LigandPNGBDBM50199195(CHEMBL3892042 | US10131658, Compound 8)
Affinity DataIC50:  0.5nMAssay Description:Inhibition of alphavbeta1 integrin (unknown origin) expressed in CHO cells assessed as inhibition of cell adhesion to fibronectin incubated for 60 mi...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetIntegrin alpha-V/beta-1(Homo sapiens (Human))
Pliant Therapeutics

Curated by ChEMBL
LigandPNGBDBM50199338(CHEMBL3932911)
Affinity DataIC50:  0.501nMAssay Description:Inhibition of integrin alphaVbeta1 (unknown origin)-mediated CHO cell adhesion to fibronectin preincubated for 15 to 30 mins followed by 60 min incub...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetIntegrin alpha-V/beta-1(Homo sapiens (Human))
Pliant Therapeutics

Curated by ChEMBL
LigandPNGBDBM50199335(CHEMBL3899812)
Affinity DataIC50:  0.501nMAssay Description:Inhibition of integrin alphaVbeta1 (unknown origin)-mediated CHO cell adhesion to fibronectin preincubated for 15 to 30 mins followed by 60 min incub...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetIntegrin alpha-V/beta-1(Homo sapiens (Human))
Pliant Therapeutics

Curated by ChEMBL
LigandPNGBDBM50199195(CHEMBL3892042 | US10131658, Compound 8)
Affinity DataIC50:  0.630nMAssay Description:Inhibition of integrin alphaVbeta1 (unknown origin)-mediated CHO cell adhesion to fibronectin preincubated for 15 to 30 mins followed by 60 min incub...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetIntegrin alpha-V/beta-1(Homo sapiens (Human))
Pliant Therapeutics

Curated by ChEMBL
LigandPNGBDBM50199195(CHEMBL3892042 | US10131658, Compound 8)
Affinity DataIC50:  0.631nMAssay Description:Inhibition of integrin alphaVbeta1 (unknown origin)-mediated CHO cell adhesion to fibronectin preincubated for 15 to 30 mins followed by 60 min incub...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetIntegrin alpha-V/beta-1(Homo sapiens (Human))
Pliant Therapeutics

Curated by ChEMBL
LigandPNGBDBM50141324(2-Isopropoxycarbonylamino-3-{2-methoxy-4-[3-(1,4,5...)
Affinity DataIC50:  0.680nMAssay Description:Binding affinity towards alpha IIb/beta3 integrin by solid-phase receptor binding assay (SPRA)More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetIntegrin alpha-V/beta-1(Homo sapiens (Human))
Pliant Therapeutics

Curated by ChEMBL
LigandPNGBDBM279573((3S)-3-(3,5-dibromophenyl)-3-[[2-[[5-[(5-hydroxy-1...)
Affinity DataIC50:  0.700nMpH: 7.4 T: 2°CAssay Description:Purified human fibronectin (R&D Systems, 1918-FN) diluted to 5 μg/mL in TBS+ buffer (25 mM Tris pH 7.4, 137 mM NaCl, 2.7 mM KCl, 1 mM CaCl2, 1 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-1(Homo sapiens (Human))
Pliant Therapeutics

Curated by ChEMBL
LigandPNGBDBM472699(US10836720, HIJ-1483)
Affinity DataIC50:  0.800nMAssay Description:Inhibition of alphavbeta1 integrin (unknown origin) expressed in CHO cells assessed as inhibition of cell adhesion to fibronectin incubated for 60 mi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetIntegrin alpha-V/beta-1(Homo sapiens (Human))
Pliant Therapeutics

Curated by ChEMBL
LigandPNGBDBM472679(US10836720, HIJ-1017)
Affinity DataIC50:  0.800nMAssay Description:Inhibition of alphavbeta1 integrin (unknown origin) expressed in CHO cells assessed as inhibition of cell adhesion to fibronectin incubated for 60 mi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetIntegrin alpha-V/beta-1(Homo sapiens (Human))
Pliant Therapeutics

Curated by ChEMBL
LigandPNGBDBM472684(US10836720, HIJ-1018)
Affinity DataIC50:  0.900nMAssay Description:Inhibition of alphavbeta1 integrin (unknown origin) expressed in CHO cells assessed as inhibition of cell adhesion to fibronectin incubated for 60 mi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetIntegrin alpha-V/beta-1(Homo sapiens (Human))
Pliant Therapeutics

Curated by ChEMBL
LigandPNGBDBM279572((3S)-3-[3-bromo-5-fluoro-phenyl)-3-(2-(3-hydroxy-5...)
Affinity DataIC50:  1nMpH: 7.4 T: 2°CAssay Description:Purified human fibronectin (R&D Systems, 1918-FN) diluted to 5 μg/mL in TBS+ buffer (25 mM Tris pH 7.4, 137 mM NaCl, 2.7 mM KCl, 1 mM CaCl2, 1 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-1(Homo sapiens (Human))
Pliant Therapeutics

Curated by ChEMBL
LigandPNGBDBM279568((3S)-3-[3-bromo-5-(trifluoromethyl)phenyl]-3-[[2-[...)
Affinity DataIC50:  1nMpH: 7.4 T: 2°CAssay Description:Purified human fibronectin (R&D Systems, 1918-FN) diluted to 5 μg/mL in TBS+ buffer (25 mM Tris pH 7.4, 137 mM NaCl, 2.7 mM KCl, 1 mM CaCl2, 1 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-1(Homo sapiens (Human))
Pliant Therapeutics

Curated by ChEMBL
LigandPNGBDBM279566((3S)-3-[3-chloro-5-(trifluoromethyl)phenyl]3-[[2-[...)
Affinity DataIC50:  1nMpH: 7.4 T: 2°CAssay Description:Purified human fibronectin (R&D Systems, 1918-FN) diluted to 5 μg/mL in TBS+ buffer (25 mM Tris pH 7.4, 137 mM NaCl, 2.7 mM KCl, 1 mM CaCl2, 1 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-1(Homo sapiens (Human))
Pliant Therapeutics

Curated by ChEMBL
LigandPNGBDBM279567((3S)-3-(3-bromo-5-chloro-phenyl)-3-[[2-[[5-[(5-hyd...)
Affinity DataIC50:  1nMpH: 7.4 T: 2°CAssay Description:Purified human fibronectin (R&D Systems, 1918-FN) diluted to 5 μg/mL in TBS+ buffer (25 mM Tris pH 7.4, 137 mM NaCl, 2.7 mM KCl, 1 mM CaCl2, 1 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-1(Homo sapiens (Human))
Pliant Therapeutics

Curated by ChEMBL
LigandPNGBDBM50141355(3-[4-(3-Guanidino-benzoylamino)-2-methoxy-phenyl]-...)
Affinity DataIC50:  1.10nMAssay Description:Binding affinity towards alpha V/beta3 receptor by solid-phase receptor binding assays (SPRA)More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetIntegrin alpha-V/beta-1(Homo sapiens (Human))
Pliant Therapeutics

Curated by ChEMBL
LigandPNGBDBM50497714(Glpg-0187 | Glpg0187)
Affinity DataIC50:  1.30nMAssay Description:Inhibition of ligand binding to integrin alphavbeta1 (unknown origin) expressed in baculovirus expression system after 2 hrs by solid-phase assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetIntegrin alpha-V/beta-1(Homo sapiens (Human))
Pliant Therapeutics

Curated by ChEMBL
LigandPNGBDBM50497714(Glpg-0187 | Glpg0187)
Affinity DataIC50:  1.30nMAssay Description:Antagonist activity at alphavbeta1 integrin receptor (unknown origin) by cell-free ELISAMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetIntegrin alpha-V/beta-1(Homo sapiens (Human))
Pliant Therapeutics

Curated by ChEMBL
LigandPNGBDBM50209461((3S)-3-(3-bromo-5-chloro-2-hydroxyphenyl)-3-(2-(3-...)
Affinity DataIC50:  1.60nMAssay Description:Antagonist activity at alphavbeta1 integrin receptor in HEK293 cells after 4 hrs using p-nitrophenyl phosphate by colorimetryMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetIntegrin alpha-V/beta-1(Homo sapiens (Human))
Pliant Therapeutics

Curated by ChEMBL
LigandPNGBDBM50497716(CHEMBL3319237)
Affinity DataIC50:  1.80nMAssay Description:Inhibition of human fibronectin binding to human integrin alphavbeta1 after 2 hrsMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetIntegrin alpha-V/beta-1(Homo sapiens (Human))
Pliant Therapeutics

Curated by ChEMBL
LigandPNGBDBM50497716(CHEMBL3319237)
Affinity DataIC50:  1.80nMAssay Description:Antagonist activity at alphavbeta1 integrin receptor (unknown origin) by cell-free ELISAMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetIntegrin alpha-V/beta-1(Homo sapiens (Human))
Pliant Therapeutics

Curated by ChEMBL
LigandPNGBDBM50199407(CHEMBL3902668 | US10131658, Compound 202)
Affinity DataIC50:  2nMAssay Description:Inhibition of integrin alphaVbeta1 (unknown origin)-mediated CHO cell adhesion to fibronectin preincubated for 15 to 30 mins followed by 60 min incub...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetIntegrin alpha-V/beta-1(Homo sapiens (Human))
Pliant Therapeutics

Curated by ChEMBL
LigandPNGBDBM279560((3S)-3-(3,5-dibromophenyl)-3-(2-(3-hydroxy-5-((5-h...)
Affinity DataIC50:  2nMpH: 7.4 T: 2°CAssay Description:Purified human fibronectin (R&D Systems, 1918-FN) diluted to 5 μg/mL in TBS+ buffer (25 mM Tris pH 7.4, 137 mM NaCl, 2.7 mM KCl, 1 mM CaCl2, 1 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-1(Homo sapiens (Human))
Pliant Therapeutics

Curated by ChEMBL
LigandPNGBDBM279561((3S)-3-(3-bromo-5-(trifluoromethyl)phenyl)-3-(2-(3...)
Affinity DataIC50:  2nMpH: 7.4 T: 2°CAssay Description:Purified human fibronectin (R&D Systems, 1918-FN) diluted to 5 μg/mL in TBS+ buffer (25 mM Tris pH 7.4, 137 mM NaCl, 2.7 mM KCl, 1 mM CaCl2, 1 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-1(Homo sapiens (Human))
Pliant Therapeutics

Curated by ChEMBL
LigandPNGBDBM279562((3S)-3-[3-chloro-5-(difluoromethyl)phenyl)-3-(2-(3...)
Affinity DataIC50:  2nMpH: 7.4 T: 2°CAssay Description:Purified human fibronectin (R&D Systems, 1918-FN) diluted to 5 μg/mL in TBS+ buffer (25 mM Tris pH 7.4, 137 mM NaCl, 2.7 mM KCl, 1 mM CaCl2, 1 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 258 total ) | Next | Last >>
Jump to: